{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:32:02Z","timestamp":1789151522539,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Myelomeningocele (MMC) is a spinal cord congenital defect that leads to paraplegia, sphincter disorders and potential neurocognitive disabilities. Prenatal surgery of MMC provides a significant benefit compared to surgery at birth. Mesenchymal stromal cell (MSC) therapy as an adjuvant treatment for prenatal surgery showed promising results in animal experiments which could be considered for clinical use in human fetuses. Despite numerous reassuring studies on the safety of MSCs administration in humans, no study focused on MSCs biodistribution after a local MSCs graft on the fetal spinal cord.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>The purpose of our study was to assess the biodistribution of umbilical cord-derived mesenchymal stromal cells (UC-MSCs) at birth in lambs who had a prenatal myelomeningocele repair using a fibrin patch seeded with allogenic UC-MSCs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>After isolation, UC-MSCs were tagged using a green fluorescent protein (GFP)-containing lentiviral vector. MMC defects were surgically created at 75\u00a0days of gestation and repaired 15\u00a0days later using UC-MSCs patch. Lambs were delivered at 142\u00a0days and sacrificed. DNA extraction was performed among biopsies of the different organs and q-PCR analysis was used to detect the expression of GFP (GFP DNA coding sequence).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In our 6 surviving lambs grafted with UC-MSCs, GFP lentivirus genomic DNA was not detected in the organs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These reassuring data will support translational application in humans, especially since the first human clinical trial using mesenchymal stromal cells for in-utero treatment of MMC started recently in U.S.A.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13287-022-02991-0","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T10:04:24Z","timestamp":1657879464000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Biodistribution of allogenic umbilical cord-derived mesenchymal stromal cells after fetal repair of myelomeningocele in an ovine model"],"prefix":"10.1186","volume":"13","author":[{"given":"Yoann","family":"Athiel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Nasone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lousineh","family":"Arakelian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Faivre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Dugas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Jouannic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Larghero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4695-9519","authenticated-orcid":false,"given":"Lucie","family":"Guilbaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"issue":"11","key":"2991_CR1","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1014379","volume":"364","author":"NS Adzick","year":"2011","unstructured":"Adzick NS, Thom EA, Spong CY, Brock JW, Burrows PK, Johnson MP, et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med. 2011;364(11):993\u20131004.","journal-title":"N Engl J Med"},{"issue":"9","key":"2991_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogoh.2021.102155","volume":"50","author":"L Guilbaud","year":"2021","unstructured":"Guilbaud L, Maurice P, Lallemant P, De Saint-Denis T, Maisonneuve E, Dhombres F, et al. Open fetal surgery for myelomeningocele repair in France. J Gynecol Obstet Hum Reprod. 2021;50(9): 102155.","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"2991_CR3","doi-asserted-by":"crossref","unstructured":"Houtrow AJ, Thom EA, Fletcher JM, Burrows PK, Adzick NS, Thomas NH, et al. Prenatal repair of myelomeningocele and school-age functional outcomes. Pediatrics. 2020;145(2).","DOI":"10.1542\/peds.2019-1544"},{"issue":"2","key":"2991_CR4","doi-asserted-by":"publisher","first-page":"256.e1","DOI":"10.1016\/j.ajog.2017.12.001","volume":"218","author":"DL Farmer","year":"2018","unstructured":"Farmer DL, Thom EA, Brock JW, Burrows PK, Johnson MP, Howell LJ, et al. The management of myelomeningocele study: full cohort 30-month pediatric outcomes. Am J Obstet Gynecol. 2018;218(2):256.e1-256.e13.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"2991_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.retram.2020.04.004","volume":"68","author":"A Dugas","year":"2020","unstructured":"Dugas A, Larghero J, Z\u00e9rah M, Jouannic JM, Guilbaud L. Cell therapy for prenatal repair of myelomeningocele: a systematic review. Curr Res Transl Med. 2020;68(4):183\u20139.","journal-title":"Curr Res Transl Med"},{"key":"2991_CR6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jpedsurg.2017.10.032","volume":"53","author":"S Kabagambe","year":"2017","unstructured":"Kabagambe S, Keller B, Becker J, Goodman L, Pivetti C, Lankford L, et al. Placental mesenchymal stromal cells seeded on clinical grade extracellular matrix improve ambulation in ovine myelomeningocele. J Pediatr Surg. 2017;53:178\u201382.","journal-title":"J Pediatr Surg"},{"issue":"6","key":"2991_CR7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.5966\/sctm.2014-0296","volume":"4","author":"A Wang","year":"2015","unstructured":"Wang A, Brown EG, Lankford L, Keller BA, Pivetti CD, Sitkin NA, et al. Placental mesenchymal stromal cells rescue ambulation in ovine myelomeningocele. Stem Cells Transl Med. 2015;4(6):659\u201369.","journal-title":"Stem Cells Transl Med"},{"issue":"9","key":"2991_CR8","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/j.jpedsurg.2019.09.029","volume":"55","author":"LA Galganski","year":"2020","unstructured":"Galganski LA, Kumar P, Vanover MA, Pivetti CD, Anderson JE, Lankford L, et al. In utero treatment of myelomeningocele with placental mesenchymal stromal cells\u2014selection of an optimal cell line in preparation for clinical trials. J Pediatr Surg. 2020;55(9):1941\u20136.","journal-title":"J Pediatr Surg"},{"issue":"1","key":"2991_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jpedsurg.2018.10.032","volume":"54","author":"M Vanover","year":"2019","unstructured":"Vanover M, Pivetti C, Lankford L, Kumar P, Galganski L, Kabagambe S, et al. High density placental mesenchymal stromal cells provide neuronal preservation and improve motor function following in utero treatment of ovine myelomeningocele. J Pediatr Surg. 2019;54(1):75\u20139.","journal-title":"J Pediatr Surg"},{"key":"2991_CR10","doi-asserted-by":"publisher","first-page":"103314","DOI":"10.1016\/j.retram.2021.103314","volume":"70","author":"L Guilbaud","year":"2021","unstructured":"Guilbaud L, Dugas A, Weber M, Deflers C, Lallemand P, Lilin T, Adam C, Mebarki M, Cras A, Z\u00e9rah M, Faivre L, Larghero JJJ. In utero treatment of myelomeningocele with allogeneic umbilical cord mesenchymal stromal cells in an ovine model. Curr Res Transl Med. 2021;70:103314.","journal-title":"Curr Res Transl Med"},{"key":"2991_CR11","unstructured":"Guideline on human cell-based medicinal products, European Medicines Agency. 2008."},{"issue":"6","key":"2991_CR12","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1177\/0963689718766279","volume":"27","author":"Z Xiao","year":"2018","unstructured":"Xiao Z, Tang F, Zhao Y, Han G, Yin N, Li X, et al. Significant Improvement of acute complete spinal cord injury patients diagnosed by a combined criteria implanted with neuroregen scaffolds and mesenchymal stem cells. Cell Transplant. 2018;27(6):907\u201315.","journal-title":"Cell Transplant"},{"issue":"9","key":"2991_CR13","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.4103\/1673-5374.276340","volume":"15","author":"W-S Deng","year":"2020","unstructured":"Deng W-S, Ma K, Liang B, Liu X-Y, Xu H-Y, Zhang J, et al. Collagen scaffold combined with human umbilical cord-mesenchymal stem cells transplantation for acute complete spinal cord injury. Neural Regen Res. 2020;15(9):1686\u2013700.","journal-title":"Neural Regen Res"},{"issue":"10","key":"2991_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047559","volume":"7","author":"MM Lalu","year":"2012","unstructured":"Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10): e47559.","journal-title":"PLoS ONE"},{"key":"2991_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/387324","volume":"2013","author":"C Adamzyk","year":"2013","unstructured":"Adamzyk C, Emonds T, Falkenstein J, Tolba R, Jahnen-Dechent W, Lethaus B, et al. Different culture media affect proliferation, surface epitope expression, and differentiation of ovine MSC. Stem Cells Int. 2013;2013: 387324.","journal-title":"Stem Cells Int"},{"issue":"1","key":"2991_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13287-021-02222-y","volume":"12","author":"M Mebarki","year":"2021","unstructured":"Mebarki M, Abadie C, Larghero J, Cras A. Human umbilical cord-derived mesenchymal stem\/stromal cells: a promising candidate for the development of advanced therapy medicinal products. Stem Cell Res Ther. 2021;12(1):152.","journal-title":"Stem Cell Res Ther"},{"issue":"7","key":"2991_CR17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jcyt.2013.03.005","volume":"15","author":"L Barkholt","year":"2013","unstructured":"Barkholt L, Flory E, Jekerle V, Lucas-Samuel S, Ahnert P, Bisset L, et al. Risk of tumorigenicity in mesenchymal stromal cell-based therapies\u2013bridging scientific observations and regulatory viewpoints. Cytotherapy. 2013;15(7):753\u20139.","journal-title":"Cytotherapy"},{"key":"2991_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.100249","volume":"19","author":"M Thompson","year":"2020","unstructured":"Thompson M, Mei SHJ, Wolfe D, Champagne J, Fergusson D, Stewart DJ, et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis. EClinicalMedicine. 2020;19: 100249.","journal-title":"EClinicalMedicine"},{"issue":"2","key":"2991_CR19","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jpedsurg.2018.10.086","volume":"54","author":"HF Shieh","year":"2019","unstructured":"Shieh HF, Tracy SA, Hong CR, Chalphin AV, Ahmed A, Rohrer L, et al. Transamniotic stem cell therapy (TRASCET) in a rabbit model of spina bifida. J Pediatr Surg. 2019;54(2):293\u20136.","journal-title":"J Pediatr Surg"},{"issue":"6","key":"2991_CR20","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.jpedsurg.2018.02.067","volume":"53","author":"HF Shieh","year":"2018","unstructured":"Shieh HF, Ahmed A, Rohrer L, Zurakowski D, Fauza DO. Donor mesenchymal stem cell linetics after transamniotic stem cell therapy (TRASCET) for experimental spina bifida. J Pediatr Surg. 2018;53(6):1134\u20136.","journal-title":"J Pediatr Surg"},{"issue":"267","key":"2991_CR21","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jss.2021.06.011","volume":"14","author":"JE Jackson","year":"2021","unstructured":"Jackson JE, Pivetti C, Stokes SC, Theodorou CM, Kumar P, Paxton ZJ, et al. Placental mesenchymal stromal cells: preclinical safety evaluation for fetal myelomeningocele repair. J Surg Res. 2021;14(267):660\u20138.","journal-title":"J Surg Res"},{"key":"2991_CR22","first-page":"1","volume":"14","author":"AV Chalphin","year":"2021","unstructured":"Chalphin AV, Lazow SP, Labuz DF, Tracy SA, Kycia I, Zurakowski D, et al. Transamniotic stem cell therapy for experimental congenital diaphragmatic hernia: structural, transcriptional, and cell kinetics analyses in the nitrofen model. Fetal Diagn Ther. 2021;14:1\u201311.","journal-title":"Fetal Diagn Ther"},{"issue":"2","key":"2991_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1124\/jpet.121.000607","volume":"379","author":"L Han","year":"2021","unstructured":"Han L, Ma C, Peng H, Wu Z, Xu H, Wu J, et al. Define mesenchymal stem cell from its fate: Biodisposition of human mesenchymal stem cells in normal and Con-A induced liver injury mice. J Pharmacol Exp Ther. 2021;379(2):125\u201333.","journal-title":"J Pharmacol Exp Ther."},{"key":"2991_CR24","unstructured":"European Medicines Agency. Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products. 2018."}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-022-02991-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-022-02991-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-022-02991-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T10:10:35Z","timestamp":1657879835000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-022-02991-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2991"],"URL":"https:\/\/doi.org\/10.1186\/s13287-022-02991-0","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]},"assertion":[{"value":"26 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was approved by the French national committee on animal research (APAFIS#2845-2015100520053611v10).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"300"}}